ReviewCurrent atherosclerosis reports2017
New-Generation Coronary Stents: Current Data and Future Directions.
Review in Current atherosclerosis reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials.Cardiovascular therapeutics · 2023Pooled it
- Mechanically Robust Biodegradable Stents With Theragenerative Vascular Responses via Combined 3D Printing and Janus Nanoengineering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nomogram Predicting In-Hospital Mortality in Patients with Myocardial Infarction Treated with Primary Coronary Interventions Based on Logistic and Angiographic Predictors.Biomedicines · 2025Article
- Mechanisms of ferroptosis and glucagon-like peptide-1 receptor agonist in post-percutaneous coronary intervention restenosis.Molecular and cellular biochemistry · 2025Review
- Antiplatelet Therapy in Low-Platelet-Count Patients After Percutaneous Coronary Intervention for Acute Coronary Syndromes.Journal of clinical medicine · 2025Review
- Stent thrombosis: a contemporary guide to definitions, risk factors, and management.Frontiers in cardiovascular medicine · 2025Review
- Fine-Tuning the Nanostructured Titanium Oxide Surface for Selective Biological Response.ACS applied bio materials · 2023Article
- Safety and Clinical Performance of Biodegradable Polymer-Coated Ultra-Thin Everolimus-Eluting Stents in "Real-World" Patients: A Multicenter Registry (PERFORM-EVER).Anatolian journal of cardiology · 2022Article
- Histone Acetyltransferases p300 and CBP Coordinate Distinct Chromatin Remodeling Programs in Vascular Smooth Muscle Plasticity.Circulation · 2022Article
- Development of In Vitro Endothelialised Stents - Review.Stem cell reviews and reports · 2022Review
- Bio-Performance of Hydrothermally and Plasma-Treated Titanium: The New Generation of Vascular Stents.International journal of molecular sciences · 2021Article
- Clinical outcomes of ultrathin biodegradable polymer-coated sirolimus-eluting stents in an all-comer population: One-year results from the T-FLEX registry including high-risk subgroups.Anatolian journal of cardiology · 2021Article
- Cardiovascular Stents: A Review of Past, Current, and Emerging Devices.Materials (Basel, Switzerland) · 2021Review
- Clinical outcomes with unselected use of an ultrathin-strut sirolimus-eluting stent: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2021Article
- Targeting smooth muscle cell phenotypic switching in vascular disease.JVS-vascular science · 2021Review
- Design of a Biocompatible Drug-Eluting Tracheal Stent in Mice with Laryngotracheal Stenosis.Journal of visualized experiments : JoVE · 2020Article
- Long-acting implants to treat and prevent HIV infection.Current opinion in HIV and AIDS · 2020Article
- Design of Self-Expanding Auxetic Stents Using Topology Optimization.Frontiers in bioengineering and biotechnology · 2020Article
- Engineering an immunomodulatory drug-eluting stent to treat laryngotracheal stenosis.Biomaterials science · 2019Article
- Most Promising Therapies in Interventional Cardiology.Current cardiology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDrug-eluting stents are the mainstay in the treatment of coronary artery disease using percutaneous coronary intervention. Innovations developed to overcome the limitations of prior generations of stents include biodegradable polymer stents, drug-eluting stents without a polymer, and bioabsorbable scaffolds. Our review briefly discusses the clinical profiles of first- and second-generation coronary stents, and provides an up-to-date overview of design, technology, and clinical safety and efficacy profiles of newer generation coronary stents discussing the relevant clinical trials in this rapidly evolving area of interventional cardiology. RECENT
findingsDrug-eluting stents have previously been shown to be superior to bare metal stents. Second-generation everolimus-eluting stents have proven to have superior outcomes compared with first-generation paclitaxel- and sirolimus-eluting stents, and the second-generation zotarolimus-eluting stents appear to be similar to the everolimus-eluting stents, though with a lesser degree of evidence. Stents with biodegradable polymers have not been shown to be superior to everolimus-eluting stents. Bioabsorbable scaffolds have not demonstrated better outcomes than current standard treatment with second-generation drug-eluting stents but have showed a concerning signal of late and very late stent thrombosis. Everolimus-eluting stents have the most favorable outcomes in terms of safety as well as efficacy in patients undergoing percutaneous coronary intervention. Newer innovations such as biodegradable polymers and bioabsorbable scaffolds lack clinical data to replace second-generation drug-eluting stents as standard of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.